Marsha R Mailick1, Jinkuk Hong1, Arezoo Movaghar1, Leann DaWalt1, Elizabeth M Berry-Kravis2, Murray H Brilliant1,3, Jaime Boero3, Peter K Todd4,5, Deborah Hall2. 1. Waisman Center, University of Wisconsin-Madison, Madison, Wisconsin, USA. 2. Department of Neurological Sciences, Rush University, Chicago, Illinois, USA. 3. Marshfield Clinic Research Institute, Marshfield, Wisconsin, USA. 4. Department of Neurology, University of Michigan, Ann Arbor, Michigan, USA. 5. Ann Arbor Veterans Administration Healthcare Center, Ann Arbor, Michigan, USA.
Abstract
BACKGROUND: Premutation-sized (55-200) CGG repeat expansions in the FMR1 gene cause fragile X-associated tremor/ataxia syndrome (FXTAS). Most studies of premutation carriers utilized reverse ascertainment to identify patients, leading to a selection bias for larger repeats. As shorter CGG premutation repeats are common in the population, understanding their impact on health outcomes has a potentially large public health footprint. OBJECTIVE: The study's objective was to compare an unselected group of premutation carriers (n = 35, 55-101 CGG repeats) with matched controls (n = 61, 29-39 CGG repeats) with respect to FXTAS-type signs using structured neurological assessments. METHODS: Three neurologists independently rated signs, using an adapted version of the FXTAS Rating Scale (Leehey MA, Berry-Kravis E, Goetz CG, et al. FMR1 CGG repeat length predicts motor dysfunction in premutation carriers. Neurology. 2008). This was a double-blind study, as genetic status (premutation vs. control) was known neither by the participants nor by any of the neurologists. Analyses controlled potentially confounding comorbid conditions in the electronic health record (eg, osteoarthritis and stroke) and probed the association of age with signs. RESULTS: Although there was no overall difference between carriers and controls, among individuals without any potentially confounding comorbid diagnoses, there was a statistically significant age-associated elevation in FXTAS-type signs in premutation carriers compared to controls. CONCLUSIONS: Among those who do not have other comorbid diagnoses, women who have CGG repeats at the lower end of the premutation range may be at greater risk for ataxia and parkinsonism than their age peers, although their overall risk of developing such clinical features is low. This study should provide reassurance to those who share characteristics with the present cohort.
BACKGROUND: Premutation-sized (55-200) CGG repeat expansions in the FMR1 gene cause fragile X-associated tremor/ataxia syndrome (FXTAS). Most studies of premutation carriers utilized reverse ascertainment to identify patients, leading to a selection bias for larger repeats. As shorter CGG premutation repeats are common in the population, understanding their impact on health outcomes has a potentially large public health footprint. OBJECTIVE: The study's objective was to compare an unselected group of premutation carriers (n = 35, 55-101 CGG repeats) with matched controls (n = 61, 29-39 CGG repeats) with respect to FXTAS-type signs using structured neurological assessments. METHODS: Three neurologists independently rated signs, using an adapted version of the FXTAS Rating Scale (Leehey MA, Berry-Kravis E, Goetz CG, et al. FMR1 CGG repeat length predicts motor dysfunction in premutation carriers. Neurology. 2008). This was a double-blind study, as genetic status (premutation vs. control) was known neither by the participants nor by any of the neurologists. Analyses controlled potentially confounding comorbid conditions in the electronic health record (eg, osteoarthritis and stroke) and probed the association of age with signs. RESULTS: Although there was no overall difference between carriers and controls, among individuals without any potentially confounding comorbid diagnoses, there was a statistically significant age-associated elevation in FXTAS-type signs in premutation carriers compared to controls. CONCLUSIONS: Among those who do not have other comorbid diagnoses, women who have CGG repeats at the lower end of the premutation range may be at greater risk for ataxia and parkinsonism than their age peers, although their overall risk of developing such clinical features is low. This study should provide reassurance to those who share characteristics with the present cohort.
Authors: Marsha Mailick Seltzer; Mei Wang Baker; Jinkuk Hong; Matthew Maenner; Jan Greenberg; Daniel Mandel Journal: Am J Med Genet B Neuropsychiatr Genet Date: 2012-05-22 Impact factor: 3.568
Authors: S L Nolin; F A Lewis; L L Ye; G E Houck; A E Glicksman; P Limprasert; S Y Li; N Zhong; A E Ashley; E Feingold; S L Sherman; W T Brown Journal: Am J Hum Genet Date: 1996-12 Impact factor: 11.025
Authors: Matthew J Maenner; Mei W Baker; Karl W Broman; Jianan Tian; Janel K Barnes; Anne Atkins; Elizabeth McPherson; Jinkuk Hong; Murray H Brilliant; Marsha R Mailick Journal: Am J Med Genet B Neuropsychiatr Genet Date: 2013-06-05 Impact factor: 3.568
Authors: Jane E Roberts; Bridgette L Tonnsen; Lindsay M McCary; Amy L Ford; Robert N Golden; Donald B Bailey Journal: Biol Psychiatry Date: 2015-07-31 Impact factor: 13.382
Authors: R J Hagerman; B R Leavitt; F Farzin; S Jacquemont; C M Greco; J A Brunberg; F Tassone; D Hessl; S W Harris; L Zhang; T Jardini; L W Gane; J Ferranti; L Ruiz; M A Leehey; J Grigsby; P J Hagerman Journal: Am J Hum Genet Date: 2004-04-02 Impact factor: 11.025
Authors: M A Leehey; E Berry-Kravis; C G Goetz; L Zhang; D A Hall; L Li; C D Rice; R Lara; J Cogswell; A Reynolds; L Gane; S Jacquemont; F Tassone; J Grigsby; R J Hagerman; P J Hagerman Journal: Neurology Date: 2007-12-05 Impact factor: 9.910
Authors: Flora Tassone; Ka Pou Iong; Tzu-Han Tong; Joyce Lo; Louise W Gane; Elizabeth Berry-Kravis; Danh Nguyen; Lisa Y Mu; Jennifer Laffin; Don B Bailey; Randi J Hagerman Journal: Genome Med Date: 2012-12-21 Impact factor: 11.117
Authors: Jinkuk Hong; Robert S Dembo; Leann Smith DaWalt; Murray Brilliant; Elizabeth M Berry-Kravis; Marsha Mailick Journal: SSM Popul Health Date: 2022-10-05